Country

NEOCUTIS® RECEIVES ITS 16th INSTYLE “BEST BEAUTY BUY” AWARD. Lumière® Recognized by InStyle as “Best Eye Cream”

Merz Aesthetics, a division of Merz North America, announced today that NEOCUTIS® Lumière was named an InStyle 2017 “Best Beauty Buy” award winner for “Best Eye Cream.” Each year the publication polls the industry’s top experts to identify the best performing beauty products. This year’s winners are featured in the May 2017 issue of InStyle.

“I have always considered NEOCUTIS® Lumière to be a leader in the eye cream category because of its innovative formula and proven results,” said Dr. Ulysses Scarpidis, board-certified plastic surgeon at Scarpidis Aesthetics in New York, NY. “Its formula is packed with a powerful blend of energizing and moisturizing ingredients to give the eye area a younger, more refreshed look. My patients that use it have never looked back.”

This year’s InStyle award marks the 16th time that NEOCUTIS® has been awarded a “Best Beauty Buy” title since 2009. Of those 16 award wins, Lumière has been honored as an InStyle “Best Beauty Buy” nine years in a row, with a total of 11 award wins.

“We are thrilled to celebrate yet another InStyle award win for NEOCUTIS® Lumière,” said Jim Hartman, Vice President and US Head of Merz Aesthetics and OTC Marketing. “The continued recognition is a true testament to the cutting-edge scientific research and technology that goes into the NEOCUTIS® formulas, that are both industry and physician approved.”

NEOCUTIS® Lumière is infused with PSP® (Processed Skin Proteins) – the brand’s patented, anti-aging technology. This exclusive technology is an optimally balanced blend of proteins, including human growth factors, that support your skin’s natural processes to preserve healthy, youthful-looking skin.

NEOCUTIS® products are available for purchase exclusively through medical practices and skincare providers. For additional information, or to find an www.MerzUSA.com authorized NEOCUTIS® Skincare provider near you, please visit www.NEOCUTIS.com.

About Merz Aesthetics

Merz Aesthetics is a division of Merz North America and offers a wide-ranging portfolio of treatment options including Device (Ultherapy®, CellfinaTM System, DESCRIBE® PFD Patch), Injectables (Xeomin®, Radiesse® Volumizing Filler, Belotero Balance®, Asclera®) and Skincare (NEOCUTIS®, Mederma®) that enable physicians to meet the needs of a broad range of patients and their skin concerns. To learn more about Merz Aesthetics, please visit www.merzusa.com/aesthetics- otc.

About Merz North America

Merz North America is a specialty healthcare company dedicated to the development and marketing of innovative quality products for physicians and patients across the United States and Canada. Merz products are distributed through two divisions, Aesthetics and Neurosciences, and are developed with the goal of improving patients’ health and quality of life by delivering therapies that bring about real progress. Merz North America is a privately-held company based in Raleigh, North Carolina. To learn more about Merz North America, please visit www.merzusa.com.

Corporate Contact
Emily Browder
Corporate Communications Merz North America
6501 Six Forks Road Raleigh, NC 27615
Office (919) 582-8114
Emily.Browder@merz.com

Press Contact

Merz North America

Emily Browder
Corporate Communications

 

Phone: +1 919.582.8114

Merz in the Americas

Merz has a direct presence in six countries in the Americas, as well as a network of selected professional distribution partners in South and Central America and the Caribbean. Merz in the Americas is headquartered in Raleigh, North Carolina, and has facilities in Mesa, Arizona, Franksville, Wisconsin as well as offices in Toronto, Canada, Mexico City, Bogotá, Colombia, São Paolo, Brazil and Buenos Aires, Argentina.

Merz Worldwide

With approximately 3,000 employees and a direct presence in 28 countries, Merz is a global, family-owned aesthetics and neurotoxin company based in Frankfurt, Germany. Privately held for 110 years, the company is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In addition to its comprehensive portfolio of medical aesthetic products in the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2016/17, Merz generated revenue of EUR 1,092.9 million. More information is available at www.merz.com.

Media Contact – Global

Merz Pharma GmbH & Co. KGaA
Global Corporate Communications
Mariana Smith Bourland
Phone: +49 151 4249 1466
Email: mariana.smith@merz.com

Media Contact – North America

Merz North America, Inc.
Corporate Communications
Emily Browder
Phone: +1 919.582.8114
Email: Emily.Browder@merz.com